Deep Survival Analysis for Interpretable Time-Varying Prediction of Preeclampsia Risk

Braden W Eberhard; Kathryn J Gray; David W Bates; Vesela P Kovacheva

doi:10.1101/2024.01.18.24301456

Abstract

Objective Survival analysis is widely utilized in healthcare to predict the timing of disease onset. Traditional methods of survival analysis are usually based on Cox Proportional Hazards model and assume proportional risk for all subjects. However, this assumption is rarely true for most diseases, as the underlying factors have complex, non-linear, and time-varying relationships. This concern is especially relevant for pregnancy, where the risk for pregnancy-related complications, such as preeclampsia, varies across gestation. Recently, deep learning survival models have shown promise in addressing the limitations of classical models, as the novel models allow for non-proportional risk handling, capturing nonlinear relationships, and navigating complex temporal dynamics.

Methods We present a methodology to model the temporal risk of preeclampsia during pregnancy and investigate the associated clinical risk factors. We utilized a retrospective dataset including 66,425 pregnant individuals who delivered in two tertiary care centers from 2015-2023. We modeled the preeclampsia risk by modifying DeepHit, a deep survival model, which leverages neural network architecture to capture time-varying relationships between covariates in pregnancy. We applied time series k-means clustering to DeepHit’s normalized output and investigated interpretability using Shapley values.

Results We demonstrate that DeepHit can effectively handle high-dimensional data and evolving risk hazards over time with performance similar to the Cox Proportional Hazards model, achieving an area under the curve (AUC) of 0.78 for both models. The deep survival model outperformed traditional methodology by identifying time-varied risk trajectories for preeclampsia, providing insights for early and individualized intervention. K-means clustering resulted in patients delineating into low-risk, early-onset, and late-onset preeclampsia groups— notably, each of those has distinct risk factors.

Conclusion This work demonstrates a novel application of deep survival analysis in time-varying prediction of preeclampsia risk. Our results highlight the advantage of deep survival models compared to Cox Proportional Hazards models in providing personalized risk trajectory and demonstrating the potential of deep survival models to generate interpretable and meaningful clinical applications in medicine.

Competing Interest Statement

Competing interests. KJG has served as a consultant to Aetion, Roche, BillionToOne, and Janssen Global Services outside the scope of the submitted work. DWB reports grants and personal fees from EarlySense, personal fees from CDI Negev, equity from Valera Health, equity from CLEW, equity from MDClone, personal fees and equity from AESOP Technology, personal fees and equity from FeelBetter, and grants from IBM Watson Health, outside the submitted work. VPK reports consulting fees from Avania CRO unrelated to the current work. VKP reports patent #WO2021119593A1 for the control of a therapeutic delivery system assigned to Mass General Brigham.

Funding Statement

KJG reports funding from NIH/NHLBI grants K08 HL146963, K08 HL146963-02S1, and R03 HL162756. VPK reports funding from the NIH/NHLBI grants 1K08HL161326-01A1, Anesthesia Patient Safety Foundation (APSF), and BWH IGNITE Award. The funders played no role in the study design, data collection, analysis, and interpretation of data, or the writing of this manuscript.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was approved by the Mass General Brigham Institutional Review Board, protocol #2020P002859, with a waiver of patient consent.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Footnotes

CRediT author statement: Braden Eberhard: Conceptualization, Methodology, Software, Writing -Original Draft; Kathryn Gray: Conceptualization, Writing – Reviewing and Editing, David Bates: Conceptualization, Writing – Reviewing and Editing, Vesela Kovacheva: Conceptualization, Methodology, Writing - Reviewing and Editing, Supervision
Competing interests. KJG has served as a consultant to Aetion, Roche, BillionToOne, and Janssen Global Services outside the scope of the submitted work. DWB reports grants and personal fees from EarlySense, personal fees from CDI Negev, equity from Valera Health, equity from CLEW, equity from MDClone, personal fees and equity from AESOP Technology, personal fees and equity from FeelBetter, and grants from IBM Watson Health, outside the submitted work. VPK reports consulting fees from Avania CRO unrelated to the current work. VKP reports patent #WO2021119593A1 for the control of a therapeutic delivery system assigned to Mass General Brigham.

Data Availability

The patient data used in this study contains identifiable protected health information and therefore cannot be shared publicly. MGB investigators with an appropriate IRB approval can contact the corresponding author directly regarding data access.